Illinois Municipal Retirement Fund Increases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Illinois Municipal Retirement Fund raised its position in Illumina, Inc. (NASDAQ:ILMN) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,357 shares of the life sciences company’s stock after acquiring an additional 646 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Illumina were worth $9,001,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ILMN. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in Illumina in the 4th quarter valued at approximately $32,000. TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the period. V Square Quantitative Management LLC raised its stake in shares of Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in Illumina by 73.5% in the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after purchasing an additional 186 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of ILMN opened at $95.73 on Wednesday. The company’s 50 day simple moving average is $126.02 and its 200-day simple moving average is $133.80. The firm has a market cap of $15.16 billion, a PE ratio of -12.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 12-month low of $91.92 and a 12-month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ILMN shares. Morgan Stanley cut their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Robert W. Baird lifted their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.